A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. - Wikidata - awgldk - TriplyDB

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

http://www.wikidata.org/entity/Q46720231

about

Extended-schedule dose-dense temozolomide in refractory gliomas Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.Controversies in the adjuvant therapy of high-grade gliomas.Bevacizumab and daily temozolomide for recurrent glioblastoma."One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.The efficacy of temozolomide for recurrent glioblastoma multiforme.Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.Dose-dense temozolomide: is it still promising?New (alternative) temozolomide regimens for the treatment of glioma.Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.Current and emerging molecular targets in glioma.Temozolomide dosing regimens for glioma patients.The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.Rechallenge with temozolomide in recurrent glioma.

P2860

Q33385736-A3FD744E-5275-4956-8323-D5680469A065 Q33392078-F70E4FBF-B6AC-4D41-8F5B-409C67363007 Q33394265-93A1F4D9-457C-4329-A014-F79A6BBE8542 Q33396384-E0064917-1726-4EDA-A689-4BDA3D823337 Q33405170-7A4408F6-9969-47ED-9839-7C3EAA6A921F Q34186787-76492FE9-0846-42A6-9C51-CFF48F86B5C3 Q34297519-A4690BB1-CE76-4C4B-913B-0EECAA8EAAA2 Q34418437-9553EDA8-40A6-4D10-B482-FF21FCAFA897 Q34992535-1A804F0A-3349-4899-85B7-3128E0D86CC8 Q35008709-50A550E6-344B-4FE6-830E-ABC4E389AE5A Q35943654-B5A874A5-4286-43D2-ADF7-596D5A8823EB Q37261125-D3810D3C-8EA8-4F8C-9C80-7ECB1D856269 Q37424389-034CB398-D8CD-493F-9638-C82AD77AD4E9 Q37809861-DBADB18E-7D75-48E7-95A7-36AF25875102 Q37995906-44719BD7-B6AE-480B-B65A-041BCF6430C1 Q38579564-BF22FA7E-E2D7-41A6-83B9-8DB983CE9179 Q39680548-B4961E2D-D50C-4E37-889C-67702835942C Q48852170-F768067B-F88D-4E27-BB25-5D23EE8C673F

P2860

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

http://www.wikidata.org/entity/Q46720231

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

A multicenter cohort study of ...... trocytoma or oligoastrocytoma.

@en

A multicenter cohort study of dose-dense temozolomide

@nl

type

label

A multicenter cohort study of ...... trocytoma or oligoastrocytoma.

@en

A multicenter cohort study of dose-dense temozolomide

@nl

prefLabel

A multicenter cohort study of ...... trocytoma or oligoastrocytoma.

@en

A multicenter cohort study of dose-dense temozolomide

@nl

P1433

Q46720231-76E200D8-20D1-4B2C-9850-EAB11249EB13

P1476

Q46720231-F4F7302D-7A3C-4736-980C-7AA071187B14

P2093

Q46720231-429C9CBB-3B95-4069-908D-88E211212ADF

Q46720231-46C7FC73-1EB5-491A-859C-6C4B1F871904

Q46720231-56FF1341-72B4-4C28-B655-13A6FFAF76D0

Q46720231-9710F44E-8375-4021-8DA7-AD270FF91502

Q46720231-AE0410EA-5416-4244-A0DF-F1865836AADD

Q46720231-BA5B4DF9-B648-4F64-BC91-997CF1C91578

Q46720231-BC23B795-32C8-41F9-824D-B9358251447D

P2860

Q46720231-0427C80C-31EF-479A-A61E-CD7E92DCAEAB

Q46720231-2D8265CE-CB27-4F1F-8FEF-90C0B34F1EA9

Q46720231-37C0AFF4-A88C-4C30-88B2-2B8995693EF2

Q46720231-48F1A53C-C3CE-4E90-B878-5D3EF062A942

Q46720231-5211DBE8-0025-4BFC-BAF0-CC2878717370

Q46720231-5C911452-5159-4DF1-850B-7AF36FB53586

Q46720231-610E8539-C98F-46E9-A808-7259FB49A5CD

Q46720231-6DC02FB1-ACF7-4254-85A1-76C4305E9A59

Q46720231-78D1A4B0-4F5F-4DF4-AB82-F3DED79C4A4F

Q46720231-8863B7AD-DE51-495F-9747-C430FAA2EDF9

P304

Q46720231-53B14615-7CE3-4547-8ED7-C6472F2A0FC8

P31

Q46720231-2E17901D-B369-4DFE-B3F5-1612C306473C

P356

Q46720231-91AEB951-C824-49D2-9A75-DB28D51E8424

P433

Q46720231-8E06F732-CA82-4504-98DA-795858DA6F94

P478

Q46720231-B0297B4C-3F44-41BD-9523-8F2656F662D4

P50

Q46720231-582F5DFD-3EBB-475E-A2CB-F99F301866A5

P577

Q46720231-FF51BB99-856F-4E4E-B868-39F58C0D352D

P698

Q46720231-D3EFD428-A7AF-445C-83C3-4B6DEE837651

P356

07357900701708393

P1433

Cancer Investigation

P1476

A multicenter cohort study of ...... strocytoma or oligoastrocytoma

@en

P2093

Alex Michotte

http://www.w3.org/2001/XMLSchema#string

Bart Neyns

http://www.w3.org/2001/XMLSchema#string

Eric Joosens

http://www.w3.org/2001/XMLSchema#string

Fabrice Branle

http://www.w3.org/2001/XMLSchema#string

Jan Sadones

http://www.w3.org/2001/XMLSchema#string

Johan Menten

http://www.w3.org/2001/XMLSchema#string

Lionel D'Hondt

http://www.w3.org/2001/XMLSchema#string

P2860

The 2007 WHO classification of tumours of the central nervous system

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Temozolomide in the treatment of recurrent malignant glioma.

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

P304

269-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07357900701708393

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18317968

http://www.w3.org/2001/XMLSchema#string